PD-1/L1

Delve into the world of PD-1/L1 in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on PD-1/L1 to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator's Advanced Therapeutics Portfolio
CompanyDeals

IASO Bio Partners with Shenzhen Longuide to Deploy LNP Technology Beyond Oncology – Broadening the Cell Therapy Innovator’s Advanced Therapeutics Portfolio

IASO Biotherapeutics (IASO Bio), a Chinese cell therapy innovator, announced a strategic partnership with Shenzhen Longuide Biopharma Corporation (Longuide), under which IASO Bio will leverage Longuide's lipid nanoparticle (LNP) technology…

China's NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

China’s NHC Issues Working Procedures for Rare Disease Catalogue (2026 Edition) – Expanded Inclusion Criteria and Faster Update Cycle Reshape Drug Access Landscape

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Nxera Pharma Licenses Oral EP4 Agonist NXE0033744 to AbbVie in up to USD 1.47 Billion IBD Deal – Validating the NxWave Discovery Platform

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
CompanyDrug

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease
CompanyDrug

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

European Commission Approves Merck's KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU
CompanyDrug

European Commission Approves Merck’s KEYTRUDA Plus Padcev for Resectable Muscle-Invasive Bladder Cancer – First and Only PD-1 Inhibitor–ADC Regimen for MIBC in the EU

Leads Biolabs' Opamtistomig Shows Positive Phase 2 Efficacy Signals in First‑Line Gastric Cancer – Anti‑PD‑L1/4‑1BB Bispecific Advances to Expansion Stage
CompanyDrug

Leads Biolabs’ Opamtistomig Shows Positive Phase 2 Efficacy Signals in First‑Line Gastric Cancer – Anti‑PD‑L1/4‑1BB Bispecific Advances to Expansion Stage

EMA's CHMP Backs Flexible Dosing for Regeneron's Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications
CompanyDrug

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors
CompanyDrug

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

FDA Approves Genentech's Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction
CompanyDrug

FDA Approves Genentech’s Tecentriq for Adjuvant Treatment of dMMR Colon Cancer – Landmark ATOMIC Trial Shows 50% Risk Reduction

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

Show More